NCT03850730尚未招募1 期
An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Cure HHT
- 入组人数
- 30
- 主要终点
- Percent change in epistaxis duration in minutes
研究概览
简要总结
Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.
详细描述
Based on frequency and nose bleed duration, a non-randomized, single arm, open label study of 30 hereditary hemorrhagic telangiectasia patients will be treated with very low dose Pazopanib [25mg-similar] for between 16 and 24 weeks.. The primary endpoint is a reduction in bleeding duration of 50% or more, along with multiple secondary related endpoints, including bleed frequency, blood counts and quality of life; as compared to 6-12 weeks of baseline characteristics. If after the first 8 weeks of therapy benefit is suboptimal, dose advance to 50mg-similar daily can be considered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This is an open label study and thus all personnel and patients will be aware of the assignment.
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •a definite diagnosis of hereditary hemorrhagic telangiectasia defined as having at least 3 of the following criteria:
- •Spontaneous and recurrent epistaxis.
- •Multiple telangiectasias at characteristic sites: lips, oral cavity, fingers, nose.
- •Visceral lesions: GI telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs.
- •A first degree relative with hereditary hemorrhagic telangiectasia according to these criteria.
- •OR a gene sequencing diagnosis of hereditary hemorrhagic telangiectasia
- •Epistaxis due to hereditary hemorrhagic telangiectasia at least 2x per week, for a cumulative duration of at least 25 minutes per week
- •Epistaxis is clinically stable during the 12 weeks prior to screening in the clinical judgment of the investigator (i.e. no major changes in frequency or duration of epistaxis).
- •Participant agrees not to undergo cautery of nasal telangiectasias or take any experimental therapies for hereditary hemorrhagic telangiectasia other than the study drug while participating in the study.
- •Male or female [non-child bearing potential]
排除标准
- •Participant has known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib that in the opinion of the investigator contradicts their participation.
- •Currently has untreated cerebral arterio-venous malformations (AVMs), cerebral arteriovenous fistulae, or cerebral cavernous malformations (CCMs) (Note: MRI scan does not need to be repeated at screening if AVMs, arterio-venous fistulas and CCMs were absent on a scan at age ≥18 years).
- •Currently has perfused pulmonary AVMs with feeding artery diameter >3mm.
- •Known significant bleeding sources other than nasal or gastrointestinal.
- •Systemic use of a vascular endothelial growth factor inhibitor in the past 3 months or previous enrollment in this study.
- •Active and recent onset of clinically significant diarrhea.
- •Current or recent (in the last 5 years) malignancies (except non-melanoma skin cancers)
- •Participant has had major surgery (e.g. surgical ligation of an AVM) or trauma within 28 days or had minor surgical procedures (e.g. central venous access line removal) within 7 days prior to dosing, the latter representing a recent wound, fracture or ulcer
- •Participant has a planned surgery during the period to include active treatment and 6 weeks of follow up.
- •Participant has clinically significant gastrointestinal abnormalities (other than hereditary hemorrhagic telangiectasia related vascular lesions)
- •Participant during the 6 months prior to first dose of study drug has a history of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism, untreated deep vein thrombosis (DVT), myocardial infarction, or any other thrombotic event.
- •QTc ≥450 msec, based on averaged QTc values of triplicate ECGs obtained over a brief recording period [The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. The same QT correction formula must be used for each individual participant to determine eligibility for and withdrawal from the study.]
- •Hgb <6 g/dL.
- •Platelets < 100x109/L.
- •International normalized ratio (INR) >1.2x upper limit of normal and activated partial thromboplastin time (aPTT)>1.2x upper limit of normal.
- •Alanine Transaminase >2x upper limit of normal.
- •Bilirubin >1.5x upper limit of normal (isolated bilirubin >1.5x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •Participant has poorly controlled hypertension [defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry [between screen and baseline]. At Screening, blood pressure must be assessed three times and the mean SBP/DBP must be <140/90 mmHg in order for a participant to be eligible for the study.]
- •Substantive renal disease (eGFR <30 mL/min/1.73m2calculated using the Cockcroft-Gault formula)
- •Echo derived left ventricular ejection fraction <30%.
- •Thyroid stimulating hormone > upper limit of normal.
- •Urine protein to creatinine ratio >0.
- •Neutrophil count <1500/mm3.
研究组 & 干预措施
Pazopanib
Experimental
Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
干预措施: Pazopanib (Drug)
结局指标
主要结局
Percent change in epistaxis duration in minutes
时间窗: Summed minutes of bleeding at baseline 3 weeks and the last 3 weeks of dosing, over16-24 weeks of dosing
A daily electronic record of each bleed, with start and end time, provides the daily epistaxis duration, compounded over each 3 weeks of study time
次要结局
- Percent change in average gushing frequency(Last 3 weeks of drug period vs baseline 3 weeks; over 16-24 weeks of dosing)
- Percent change in average bleed frequency(Last 3 weeks compared to the baseline 3 weeks; over 16-24 weeks of dosing)
- Absolute [gm/dl] change in serum hemoglobin(comparing last 6 weeks to baseline 3-6 weeks; over 16-24 weeks of drug dosing)
- Change in the frequency of blood transfusions(Final 6 weeks of study, compared to baseline 3-6 weeks; over 16- 24 weeks of dosing)
- Daily monitoring for change in diastolic blood pressure [mm mercury](Daily from baseline through up to 24 weeks till on-drug study completion)
- Change in the frequency of IV iron infusions(Last 6 weeks of dosing to first 6 weeks; over 16-24 weeks of drug administration)
- Percent change in the per bleed average epistaxis severity(The final 3 weeks to the baseline 3 weeks of the study; for a16-24 week duration study)
- Daily monitoring for change in systolic blood pressure [mm mercury] using daily recordings(Daily from baseline through up to 24 weeks till on-drug study completion.)
- Number of participants with changes in alanine aminotransferase [liver function test](Baseline and throughout the 16-24 week dosing period)
- Monitor for active and safe trough serum drug concentrations(Over 16-24 week duration of study; once at steady state for each administered dose)
- Evaluate for change in composite mental quality of life scores(baseline, week 12 and at study drug-dosing end; 16, 20 or 24weeks)
- Evaluate for change in composite physical quality of life scores(baseline, week 12 and at study drug-dosing end; up to 24 weeks.)
- Evaluate for change in fatigue composite scores(baseline and study end; up to 24 weeks)
研究者
相似试验
已完成
2 期
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple MyelomaCarcinoma, Renal CellNCT00256880GlaxoSmithKline100
已完成
4 期
Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A PatientsHemophilia ANCT00914459Pfizer37
Unknown
不适用
Trial for the Treatment of Pelvic and Back Pain in PregnancyPelvic Girdle PainSymphysio Pubic DysfunctionNCT00830934University College Cork226
终止
2 期
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)Macular DegenerationNCT01362348GlaxoSmithKline19
已完成
不适用
PillSense System for Detecting UGI BleedUGI BleedUpper Gastrointestinal BleedingUpper Gastrointestinal BleedNCT05385224EnteraSense Limited131